Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
India · Delayed Price · Currency is INR 2,639.00
+15.20 (0.58%)
Aug 11, 2026, 3:30 PM IST
Caplin Point Laboratories Revenue
In the fiscal year ending March 31, 2026, Caplin Point Laboratories had annual revenue of 21.87B INR with 12.77% growth. Caplin Point Laboratories had revenue of 6.00B in the quarter ending March 31, 2026, with 18.95% growth.
Revenue
21.87B
Revenue Growth
+12.77%
P/S Ratio
9.12
Revenue / Employee
5.51M
Employees
3,966
Market Cap
199.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 21.87B | 2.48B | 12.77% |
| Mar 31, 2025 | 19.40B | 2.43B | 14.35% |
| Mar 31, 2024 | 16.96B | 2.28B | 15.51% |
| Mar 31, 2023 | 14.68B | 1.97B | 15.53% |
| Mar 31, 2022 | 12.71B | 2.09B | 19.64% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emcure Pharmaceuticals | 96.83B |
| Piramal Pharma | 92.05B |
| Alembic Pharmaceuticals | 77.84B |
| Strides Pharma Science | 50.04B |
| Akums Drugs and Pharmaceuticals | 45.08B |
| NATCO Pharma | 40.78B |
| Wockhardt | 36.64B |
| Eris Lifesciences | 32.12B |
Caplin Point Laboratories News
- 2 months ago - Top gainers in morning trade: balaji amines at ₹2,237.30 up 7.00%, ola electric mobility at ₹47.51 up 6.93%, caplin point laboratories at ₹2,216.00 up 4.97% - Business Upturn
- 3 months ago - Caplin Point Laboratories Transcript: Q4 25/26 - Transcripts
- 3 months ago - Caplin Point Laboratories Slides: Q4 2026 - Filings
- 3 months ago - Caplin Point Laboratories Quarterly report: Q4 2026 - Filings
- 3 months ago - Caplin Point subsidiary receives USFDA approval for Calcium Gluconate Injection; targets $71 million US market - Business Upturn
- 5 months ago - Caplin Point receives USFDA approval for potassium phosphates injection - Business Upturn
- 5 months ago - Caplin Point Laboratories arm receives USFDA approval for potassium phosphates injection - Business Upturn
- 5 months ago - Caplin Point subsidiary secures USFDA final approval for Desmopressin Acetate Injection ANDA - Business Upturn